
    slow accrual
  
['lymphoma']
['pegfilgrastim', 'loratadine']

        Inclusion Criteria:

          1. Patients must have newly diagnosed, previously untreated Diffuse Large B-cell
             Lymphoma, Mantle Cell Lymphoma, Grade 3B Follicular lymphoma, Burkitt Lymphoma,
             Peripheral T cell Lymphoma NOS, NK/T cell Lymphoma, or Transformed lymphoma.

          2. Planned to receive chemotherapy for 6 cycles which the treating physician plans to
             utilize for pegfilgrastim to minimize risk for neutropenic fever, including but not
             limited to R-CHOP, R-EPOCH, and R-HyperCVAD, CHOP, and SMILE.

          3. Age >= 18 years old.

          4. ECOG performance status 0-3.

          5. Ability to provide informed consent for participation.

        Exclusion Criteria:

          1. Existing chronic bone pain prior to pegfilgrastim usage.

          2. Creatinine clearance of <50ml/minute by Cockcroft Gault equation.

          3. Allergy to filgrastim, pegfilgrastim, or Loratadine.

          4. Chronic daily usage of antihistamine without an acceptable alternative
             non-antihistamine medication.

          5. Inability to swallow medications.

          6. Inability to complete the survey instrumentation accurately.
      